[1] GAO Chun-yang, SONG Chang-mei, FU Yan-lai, et al. Curative Effect on Treating COVID-19 by Integrated Medicine: A Systematic Review [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2021, 44(01): 1-9. [doi: 10.13424/j.cnki.jsctcm.2021.01.001]
Curative Effect on Treating COVID-19 by Integrated Medicine: A Systematic Review
- Article number:
- 2096-1340(2021)01-0001-09
- Keywords:
- New coronary virus pneumonia; COVID - 19; Integrated Medicine; Meta - analysis; Systematic Review
- ZTFLH:
- R256.1
- Code:
- A
- Abstract:
- Objective: To give a systematic appraisal of the curative effect on treating COVID - 19 by Integrated Medicine. Methods: To search the relevant studies on the treatment of COVID - 19 with the integration of Chinese and Western Medicine in the Chinese Corpus ranging from December 12th,2019 to March 25th,2020. The Meta - analysis of the data is done by Stata15. 1 until two appraiser independently search and select the documents, then extract the information and evaluate the risk of bias. Results: 912 cases among 12 studies are selected and grouped into 4 RCT and 8 non - random research respectively. The result of Meta shows that the overall curative effect of treatment with Chinese and Western Medicine significantly rise[RR = 1. 313,95% CI(1. 105,1. 560),P = 0. 002],the difference value of clinical syndrome score increase [SMD = 0. 818,95% CI(0. 03,1. 616),P = 0,042],the control rate of fever increases [RR = 1. 296,95% CI(1. 161,1. 447),P < 0. 0001],the duration of fever shortens [ WMD = - 1. 577,95% CI( - 1. 980, - 1. 173),P < 0. 0001],the improvement rate of debilitation increase [RR = 1. 553,95% CI(1. 213,1. 990),P < 0. 0001], the difference value of debilitation increase[SMD = 1. 489,95% CI(0. 679,2. 300),P < 0. 0001],the duration of debilitation shortens[WMD = - 1. 742,95% CI( - 2. 006, - 1. 478),P < 0. 0001],the improvement rate of cough increase[RR = 1. 653,95% CI(1. 341,2. 036),P < 0. 0001],the difference value of cough increase[SMD = 1. 951,95% CI(1. 127,2. 774),P < 0. 0001],the duration of cough shortens[WMD = - 1. 711,95% CI( - 2. 303, - 1. 119),P < 0. 0001],the improvement rate of CT increase[RR = 1. 278,95% CI(1. 040,1. 571),P = 0. 019],the rate of transforming to severe declines[RR = 0. 438,95% CI(0. 258,0. 673),P < 0. 0001];the difference value before and after fever and the difference value of the negative transformation rate have no statistical significance. Conclusion: The overall curative rate, overall clinical symptom scores, the control rate of fever and its duration, the improvement of debilitation, the difference value and its duration, the improvement rate of cough and the difference value as well as its duration, the improvement rate of CT and rate of transforming severe are generally superior to the group treated uniquely by Western Medicine. It is suggested that the treatment of COVID - 19 with the combination of Chinese and Western Medicine is significant. However, the result needs to be further testified since the selected studies are controlled in terms of quantity and quality.
References:
[1]詹志来,刘佳,杨伟,等.基于病例分析的中医药治疗新型冠状病毒肺炎疗效评价标准的探索研究[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200312.0949.002.html.
[2]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[EB/OL].2020,3,3.http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[3]国新办就中医药防治新冠肺炎的重要作用及有效药物举行发布会,2020,3,23.http://www.china.com.cn/zhibo/content_75844688.htm.
[4]程琦,高杉,于春泉.新型冠状病毒肺炎的中西医防治研究进展[J/OL].天津中医药.http://kns.cnki.net/kcms/detail/12.1349.R.20200320.1526.002.html.
[5] Higgins JPT,Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0.The Chorane Collaboration,2011. Available at:http://www.handbook.cochrane.org/.
[6]Stang A. Critical evaluation of the Newcastle - Ottawa scale for theassessment of the quality of nonrandomized studies in meta - analyses[J]. Eur J Epidemiol,2010,25(9):603 - 605.
[8]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第四版)[EB/OL].2020-1-27.http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml.
[9]国家卫生健康委员会,国家中医药管理局办公室.关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-2-4].http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
[10]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].2020-2-18.http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[11]程德忠,王文菊,李毅,等.51例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析:多中心回顾性研究[J/OL].天津中医药.http://kns.cnki.net/kcms/detail/12.1349.R.20200310.1024.004.html.
[12]黄海,赵焰,左星河,等.肺炎一号方、肺炎二号方治疗新型冠状病毒肺炎[J/OL].中医学报.http://kns.cnki.net/kcms/detail/41.1411.R.20200323.1016.002.html.
[13]段璨,夏文广,郑婵娟,等.金花清感颗粒治疗新型冠状病毒感染肺炎的临床观察[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200323.0853.002.html.
[14]丁晓娟,张勇,何东初,等.清肺透邪扶正方治疗新型冠状病毒肺炎的临床疗效及机制研究[J/OL].医药导报.http://kns.cnki.net/kcms/detail/42.1293.R.20200302.1615.002.html.
[15]杨明博,党双锁,黄胜,等.热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201321.
[16]瞿香坤,郝树立,马景贺,等.疏风解毒胶囊联合阿比多尔治疗新型冠状病毒肺炎的回顾性研究[J].中草药,2020,57(5):1167-1170.
[17]傅晓霞,林路平,谭行华.透解祛瘟颗粒治疗新型冠状病毒肺炎临床观察[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201314.
[18]时佳,杨宗国,叶晨,等.中西医结合治疗上海地区49例非危重型新型冠状病毒肺炎临床疗效观察[J/OL].上海中医药杂志.https://doi.org/10.16305/j.1007-1334.2020.04.095.
[19]夏文广,安长青,郑婵娟,等.中西医结合治疗新型冠状病毒肺炎34例临床研究[J]中医杂志,2020,61(5):375-381.
[20]傅晓霞,林路平,谭行华.中西医结合治疗新型冠状病毒肺炎37例临床研究[J/OL].中药新药与临床药理.http://kns.cnki.net/kcms/detail/44.1308.R.20200319.1644.002.html.
[21]吕睿冰,王文菊,李欣.中药连花清瘟治疗新型冠状病毒肺炎疑似病例63例临床观察[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200215.1633.004.html.
[22]姚开涛,刘明瑜,李欣,等.中药连花清瘟治疗新型冠状病毒肺炎的回顾性临床分析[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201099.
[23]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:168-189.
[24]杨家耀,苏文,乔杰,等.90例普通型新型冠状病毒肺炎患者中医证候与体质分析[J/OL].中医杂志,2020,61(8):645-649.
[25]林琳,唐光华,欧爱华,等.103例SARS住院患者中医证候规律探讨[J]中医杂志,2004,45(1):51-52.
[26]管汉雄,熊颖,申楠茜,等.新型冠状病毒肺炎(COVID-19)临床影像学特征[J/OL].放射学实践.https://doi.org/10.13609/j.cnki.1000-0313.2020.02.001.
[27]钟飞扬,张寒菲,王彬宸,等.新型冠状病毒肺炎的CT影像学表现[J/OL].武汉大学学报(医学版).https://doi.org/10.14188/j.1671-8852.2020.0061.
[28]Wang M,Cao R,Zhang L,et,al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019 - nCoV) in vitro[ J]. Cell Res,2020,30(3): 269 - 271.
Memo
基金项目:第四批全国优秀临床人才项目(国中医药人教发[2017]24号);国家中医药管理局全国中医学术流派传 承工作室第二轮建设项目(国中医人教函[2019]62号)
通讯作者:张晋,中医学博士,主任医师。 E-mail:13911893296@163.Com